CN116875535A - Smog disease vascular organoid model and construction method thereof - Google Patents
Smog disease vascular organoid model and construction method thereof Download PDFInfo
- Publication number
- CN116875535A CN116875535A CN202310888004.7A CN202310888004A CN116875535A CN 116875535 A CN116875535 A CN 116875535A CN 202310888004 A CN202310888004 A CN 202310888004A CN 116875535 A CN116875535 A CN 116875535A
- Authority
- CN
- China
- Prior art keywords
- fgf
- collagen
- vegf
- vascular
- smog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 52
- 210000002220 organoid Anatomy 0.000 title claims abstract description 47
- 201000010099 disease Diseases 0.000 title claims abstract description 46
- 230000002792 vascular Effects 0.000 title claims abstract description 34
- 238000010276 construction Methods 0.000 title claims abstract description 20
- 239000002609 medium Substances 0.000 claims abstract description 66
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 19
- 239000000556 agonist Substances 0.000 claims abstract description 17
- 239000001963 growth medium Substances 0.000 claims abstract description 17
- 230000004069 differentiation Effects 0.000 claims abstract description 16
- 210000003716 mesoderm Anatomy 0.000 claims abstract description 15
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 210000005167 vascular cell Anatomy 0.000 claims abstract description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 9
- 239000003112 inhibitor Substances 0.000 claims description 38
- 210000002966 serum Anatomy 0.000 claims description 36
- 239000000779 smoke Substances 0.000 claims description 25
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 24
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 24
- 102000008186 Collagen Human genes 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 23
- 229920001436 collagen Polymers 0.000 claims description 23
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 22
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 21
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 17
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 17
- 210000002744 extracellular matrix Anatomy 0.000 claims description 17
- -1 CBM1078 Chemical compound 0.000 claims description 16
- 239000007640 basal medium Substances 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 14
- 102000012422 Collagen Type I Human genes 0.000 claims description 13
- 108010022452 Collagen Type I Proteins 0.000 claims description 13
- 230000000996 additive effect Effects 0.000 claims description 13
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 12
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 11
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 11
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 11
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 11
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 108010082117 matrigel Proteins 0.000 claims description 9
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 8
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 8
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 8
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 8
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 102100037362 Fibronectin Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 claims description 7
- 102000006083 ZNRF3 Human genes 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 229960005322 streptomycin Drugs 0.000 claims description 7
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 claims description 6
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims description 6
- 108010085895 Laminin Proteins 0.000 claims description 6
- 102000007547 Laminin Human genes 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 102100025036 Norrin Human genes 0.000 claims description 4
- 101710085992 Norrin Proteins 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- RBORURQQJIQWBS-FHIGPPGSSA-N (Sp)-8-bromo-cAMPS Chemical compound C([C@H]1O2)O[P@@](S)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br RBORURQQJIQWBS-FHIGPPGSSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010059616 Activins Proteins 0.000 claims description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 3
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims description 3
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 3
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims description 3
- 108050003237 Fibroblast growth factor 11 Proteins 0.000 claims description 3
- 102100028413 Fibroblast growth factor 11 Human genes 0.000 claims description 3
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 3
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims description 3
- 102000003685 Fibroblast growth factor 14 Human genes 0.000 claims description 3
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 claims description 3
- 108050002072 Fibroblast growth factor 16 Proteins 0.000 claims description 3
- 102100035307 Fibroblast growth factor 16 Human genes 0.000 claims description 3
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 claims description 3
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 3
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims description 3
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims description 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 3
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 3
- 108050002062 Fibroblast growth factor 22 Proteins 0.000 claims description 3
- 102100024804 Fibroblast growth factor 22 Human genes 0.000 claims description 3
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims description 3
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 3
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 3
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 3
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 3
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 3
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 3
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims description 3
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims description 3
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 3
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 3
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 3
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 3
- 101000878182 Mus musculus Fibroblast growth factor 15 Proteins 0.000 claims description 3
- 102100035194 Placenta growth factor Human genes 0.000 claims description 3
- 108091078718 R-spondin family Proteins 0.000 claims description 3
- 102000041829 R-spondin family Human genes 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 3
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 3
- 239000000488 activin Substances 0.000 claims description 3
- 229960002648 alanylglutamine Drugs 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 3
- VIRRLEDAYYYTOD-YHEOSNBFSA-N colforsin daropate hydrochloride Chemical compound Cl.O[C@H]([C@@]12C)CCC(C)(C)[C@@H]1[C@H](OC(=O)CCN(C)C)[C@H](OC(C)=O)[C@]1(C)[C@]2(O)C(=O)C[C@](C)(C=C)O1 VIRRLEDAYYYTOD-YHEOSNBFSA-N 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 3
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims description 3
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229960002518 gentamicin Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 239000000893 inhibin Substances 0.000 claims description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 3
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 claims description 3
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 3
- 229950005741 rolipram Drugs 0.000 claims description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 2
- FQCPPVRJPILDIK-UHFFFAOYSA-N chembl126077 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=CC=C21 FQCPPVRJPILDIK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002986 dinoprostone Drugs 0.000 claims description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 101100288960 Mus musculus Lefty1 gene Proteins 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 37
- 210000004204 blood vessel Anatomy 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000001338 self-assembly Methods 0.000 abstract description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 14
- 108050003627 Wnt Proteins 0.000 description 12
- 102000013814 Wnt Human genes 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 9
- 229940126864 fibroblast growth factor Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102100027418 E3 ubiquitin-protein ligase RNF213 Human genes 0.000 description 7
- 101000650316 Homo sapiens E3 ubiquitin-protein ligase RNF213 Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000002771 cell marker Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 3
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 3
- 102100037369 Nidogen-1 Human genes 0.000 description 3
- 230000004156 Wnt signaling pathway Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- GHKCSRZBNZQHKW-UHFFFAOYSA-N 1-sulfanylethanol Chemical compound CC(O)S GHKCSRZBNZQHKW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 102100038446 Claudin-5 Human genes 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101100317380 Danio rerio wnt4a gene Proteins 0.000 description 1
- 101100428956 Danio rerio wnt8b gene Proteins 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 101710157159 E3 ubiquitin-protein ligase RNF213 Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102100021259 Frizzled-1 Human genes 0.000 description 1
- 102100039820 Frizzled-4 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000882896 Homo sapiens Claudin-5 Proteins 0.000 description 1
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000855004 Homo sapiens Protein Wnt-7a Proteins 0.000 description 1
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 101150017554 LGR5 gene Proteins 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 101100485095 Mus musculus Wnt10b gene Proteins 0.000 description 1
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 1
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102100020729 Protein Wnt-7a Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102100022762 R-spondin-1 Human genes 0.000 description 1
- 102100022759 R-spondin-4 Human genes 0.000 description 1
- 101710110307 R-spondin-4 Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150010310 WNT-4 gene Proteins 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 101000770767 Xenopus laevis Protein Wnt-2b-A Proteins 0.000 description 1
- 102000036513 ZNRFs Human genes 0.000 description 1
- 108091007334 ZNRFs Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000275 circle of willis Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- PNMUAGGSDZXTHX-UHFFFAOYSA-N glycyl-glutamine Chemical compound NCC(=O)NC(C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000026762 inability to speak Diseases 0.000 description 1
- HBDSHCUSXQATPO-BGBJRWHRSA-N indirubin-3'-monoxime Chemical compound O=C/1NC2=CC=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 HBDSHCUSXQATPO-BGBJRWHRSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a smog blood vessel organoid model and a construction method thereof, wherein the construction method comprises the steps of using a culture medium containing WNT agonist and TGF-beta superfamily to induce differentiation of iPSC from smog patients to obtain mesoderm; inducing differentiation of the mesoderm using a medium containing VEGF and cAMP agonists to obtain vascular cells; and (3) inducing the vascular cells by using a culture medium containing VEGF and FGF to obtain a vascular network structure, and finally successfully constructing the smog vascular organoid model. The smog disease vascular organoid model can observe the three-dimensional environment and self-assembly of tissues, captures important intermediate cell types and genetic information of all development stages, is more comprehensive, is convenient and quick to obtain in vitro, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of organoids, and relates to a smog vascular organoid model and a construction method thereof.
Background
Smog disease (MMD) is a chronic cerebrovascular disease and is a common cause of cerebral apoplexy in children and young adults in China. It is characterized by progressive occlusion or stenosis of the internal carotid artery and the terminal part of its main branch, forming an abnormal network of aerosol blood vessels at the base of the skull. Cerebrovascular events caused by carotid stenosis or occlusion and branch vessel rupture are the major clinical manifestations. At present, the etiology and pathogenesis of the smog disease are not clear, and research shows that the smog disease is related to heredity, inflammation, infectious lesions, abnormal secretion of cytokines, immune response and the like. Pathologies are manifested by thickening of the intimal fibrocyte, irregular relief of the elastic layer, thinning of the media, and abnormal deposition of extracellular matrix.
In 2011, the first susceptibility gene of smoke disease was found to be ring finger protein 213 (ring finger protein, RNF 213), which is the most common susceptibility gene for asian smoke patients, and the risk of onset of smoke disease in carrier with RNF213 p.r4810k (rs 112735431) mutation was significantly increased. Current studies on smoke disease fail to reveal key mechanisms by which RNF213 mutations lead to or are involved in the pathogenesis of smoke disease, and existing models of smoke disease do not mimic the pathogenesis of smoke disease, so the lack of clinical specimens and animal models has hindered the progress of the study. In order to study the pathogenesis of smoke disease, there is an urgent need to explore new disease models and new therapeutic strategies.
Disclosure of Invention
In order to make up the defects of the prior art, the invention aims to provide a smog disease vascular organoid model, and a construction method and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
the first aspect of the invention provides a construction method of a smog vessel organoid model, which comprises the following steps:
(1) Inducing differentiation of ipscs derived from smog patients into mesoderm;
(2) Inducing mesoderm described in step (1) to produce a vascular network structure;
(3) The vascular network structure described in the culturing step (2) is formed into a vascular organoid model.
Further, the specific steps of the step (1) include: differentiation of the ipscs was induced using medium containing WNT agonist and TGF- β superfamily to obtain mesoderm.
Further, the WNT agonist comprises one or more of the WNT family, the R-spondin family, norrin, GSK-inhibitor, RNF43 inhibitor, or ZNRF3 inhibitor.
Further, the GSK-inhibitor comprises SB216763, SB 415286, GSK-3 inhibitor, RNF43 inhibitor or ZNRF3 inhibitor.
Further, the GSK-3 inhibitor comprises a GSK-3 alpha inhibitor or a GSK-3 beta inhibitor.
Further, the GSK-3 ss inhibitors include CHIR99021, TD114-2, BIO (6-bromoindirubin-30-acetoxime), kenpaullone, TWS119, CBM1078, SB216763, 3F8 (TOCRIS), AR-A014418, FRATide, indirubin-3' -oxide or L803.
Further, the GSK-3 beta inhibitor is CHIR99021.
Further, the concentration of CHIR99021 was 12 μm.
Further, the TGF-beta superfamily includes TGF-beta proteins, BMP, GDF, GDNF, activin, lefty, mulllerian inhibitor, inhibin, or Nodal.
Further, the BMP includes BMP2, BMP4, BMP6, or BMP7.
Further, the BMP is BMP4.
Further, the concentration of BMP4 was 30ng/mL.
Further, the culture medium containing WNT agonist and TGF-beta superfamily also includes basal medium, serum substitute, glutamine or its substitute, sulfhydryl reducing agent, and antibiotic.
Further, the iPSC confluence is selected from 40-70%.
Further, the culturing time of the step (1) is from day0 to day 3.
Further, the specific steps of the step (2) include:
(a) Inducing differentiation of the mesoderm to obtain vascular cells;
(b) Embedding the vascular cells in the step (a) in an extracellular matrix for incubation, and inducing the vascular cells to differentiate and bud by using a culture medium containing VEGF and FGF after incubation to obtain a vascular network structure.
Further, the mesoderm was induced to differentiate using medium containing VEGF and cAMP agonist.
Further, the VEGF comprises one or more of VEGF-A, VEGF-B, VEGF-C, VEGF-D, PGF.
Further, the VEGF is VEGF-A.
Further, the concentration of VEGF-A was 100ng/mL.
Further, the cAMP agonists include one or more of forskolin, IBMX, rolipram, 8BrcAMP, PGE2, NKH 477, DBcAMP, sp-8-Br-cAMPs.
Further, the cAMP agonist is forskolin.
Further, the concentration of forskolin is 2 μm.
Further, the FGF comprises one or more of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23.
Further, the FGF is FGF-2.
Further, the FGF-2 concentration is 100ng/mL.
Further, the extracellular matrix comprises one or more of collagen, matrigel, gelatin, laminin, fibronectin, hyaluronic acid and chitosan.
Further, the extracellular matrix is collagen and Matrigel.
Further, the Collagen includes Collagen-I, collagen-II, collagen-III, collagen-IV, collagen-V, collagen-VI or Collagen-VII.
Further, the Collagen is Collagen-I.
Further, the concentration of Collagen-I was 2.0mg/mL.
Further, the pH of the Collagen-I was 7.4.
Further, the mixing ratio of the collagen and Matrigel is 4:1.
Further, the incubation conditions were 37℃for 2h.
Further, the extracellular matrix was also mixed with NaOH, DMEM, HEPES, sodium bicarbonate, glutamine, ham's F-12.
Further, the concentration of sodium bicarbonate was 7.5%.
Further, the culture medium containing VEGF and cAMP agonists also comprises basal medium, serum substitute, glutamine or substitute thereof, sulfhydryl reducing agent, and antibiotics.
Further, the culture medium containing VEGF and FGF also comprises SFM culture medium and serum.
Further, the serum includes FBS, calf serum, horse serum, goat serum or human serum.
Further, the serum is FBS.
Further, the culturing time of the step (a) is from 3 rd day to 4 th day.
Further, the culturing time of the step (b) is from 5 th day to 10 th day.
Further, the specific steps of the step (3) include: the vascular network structure described in step (2) was cultured with a medium containing VEGF and FGF to form a vascular organoid model.
Further, the basal medium comprises one or more of DMEM, IMDM, DMEM/F12, F10 and BME, MEM, neurobasal.
Further, the basal medium is DMEM/F12 medium and neurobasal medium.
Further, the serum replacement comprises KOSR, B27 additive, N2 additive, physiologix TM XF SR、StemSure TM SerumSubstitute Supplement、Knockout TM One or more of the SRs.
Further, the serum replacement is a B27 additive and an N2 additive.
Further, the glutamine or a substitute thereof comprises glutamine, L-alanyl-L-glutamine, hyCyte TM GluMax、glutaGRO TM One or more of them.
Further, the glutamine or a substitute thereof is glutamine.
Further, the sulfhydryl reducing agent comprises one or more of beta-mercaptoethanol and dithiothreitol.
Further, the sulfhydryl reducing agent is beta-mercaptoethanol.
Further, the antibiotics comprise one or more of penicillin-streptomycin, gentamicin and vancomycin.
Further, the antibiotic is penicillin-streptomycin.
Further, the route of acquisition of ipscs from the patient of the smoke disease includes commercial purchase or self-construction.
Further, the smoke patient is a smoke patient carrying a mutation in RNF 213.
In a second aspect the invention provides a smog disease vascular organoid model obtained by the construction method according to the first aspect of the invention.
In a third aspect, the invention provides the use of an organoid model according to the second aspect of the invention for screening for a medicament for the prophylaxis and/or treatment of smog disorders.
In a fourth aspect, the invention provides the use of a smog vessel organoid model according to the second aspect of the invention for the manufacture of a product for evaluating the efficacy of a smog therapeutic drug.
In a fifth aspect, the present invention provides the use of a smoky vascular organoid model according to the second aspect of the invention for evaluating a smoky detection product or method of non-diagnostic interest.
In a sixth aspect, the invention provides the use of a smoke disease organoid model according to the second aspect of the invention for the construction of a smoke disease animal model.
The invention has the advantages and beneficial effects that:
the method for constructing the smog disease blood vessel organoid model can successfully construct the smog disease three-dimensional blood vessel organoid model carrying the susceptibility gene RNF213 mutation, and the smog disease three-dimensional blood vessel organoid model constructed by the method can observe the self-assembly of a three-dimensional environment and tissues, and solve the biological process which can not be observed in a two-dimensional environment; compared with the construction of a gene editing cell line, the smog vascular organoid model constructed based on patient-derived iPSC cells has more comprehensive genetic background information; the smog disease blood vessel organoid model constructed by the invention can also study the interaction between blood vessel wall cells, and compared with the single differentiation of a certain cell, the organoid can better simulate the in-vivo environment.
Drawings
FIG. 1 is a graph showing the results of reprogramming skin cells to iPSCs, wherein 1A is a graph showing the results of skin cell morphology (4X) and 1B is a graph showing the results of iPSC clones grown on MEFs (4X);
FIG. 2 is a graph of the results of immunofluorescent staining to identify the pluripotency of iPSC;
FIG. 3 is a graph showing the results of a successful construction of a model of a smog vessel organoid, wherein 3A is a schematic diagram of the differentiation flow of iPSC, 3B is a graph showing the results of morphological features of various stages in the construction of a model of a smog vessel organoid, 3C is a graph showing the results of immunofluorescence detection of CD31 expression in cells, 3D is a graph showing the results of immunofluorescence detection of CD31 expression (4 x) in mature smog vessel organoids, and 3E is a graph showing the results of immunofluorescence detection of CD31 expression (20 x) in mature smog vessel organoids;
FIG. 4 is a graph showing the results of a single cell sequencing experiment, wherein 4A is a single cell sequencing UMAP dimension reduction visualization and cell grouping annotation graph of a smoke disease and a healthy control, 4B is a cell grouping duty cycle graph of a smoke disease and a healthy control in a vascular-like organ, 4C is a gene expression graph of an endothelial cell marker PECAM1, 4D is a gene expression graph of an endothelial cell marker CLDN5, 4E is a gene expression graph of an endothelial cell marker SOX17, 4F is a gene expression graph of a wall cell marker PDGFRB, 4G is a gene expression graph of a fibroblast marker DCN, and 4H is a gene expression graph of a smooth muscle cell marker PDGFRA;
fig. 5 is a graph showing the results of a flow cytometry experiment, wherein 5A is a graph showing the results of flow analysis of smooth muscle marker CD140B from vascular organoids of smoke disease and healthy controls, and 5B is a graph showing the flow results of statistical analysis. And (3) injection: DAPI in fig. 2 is 4', 6-diamidino-2-phenylindole, a fluorescent dye.
Detailed Description
The following provides definitions of some of the terms used in this specification. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
In the present invention, the term "smoky disease" or "smoky syndrome" or "MMD" refers to stenotic occlusive disease of cerebral arteries involving smooth muscle cell proliferation with intimal hyperplasia, resulting in arterial stenosis and occlusion around the viruse's ring (circle of Willis). It involves the formation of new blood vessels resembling "smoke" ("smoky") in subcortical areas. MMD occurs in children and adults with two peaks-the first peak occurring around the age of 5 to 10 years and the second peak occurring between the third and fifth decade of life. Common symptoms include headache or dizziness, weakness or paralysis of the limbs or body side, speech problems-inability to speak or recall words, sensory or cognitive impairment, involuntary movements, seizures or loss of consciousness, vision problems, stroke and cerebral hemorrhage. 80% of MMD cases are carriers of RNF213 and/or R4810K mutations. The treatment options for MMD involve daily use of aspirin, changing lifestyle to maximize brain perfusion, and surgical direct or indirect bypass to restore blood flow.
In the present invention, the term "iPSC" or "induced pluripotent stem cell" refers to a stem cell which is capable of being cultured in vitro and has the ability to differentiate into any cell (tricdermal (ectodermal, mesodermal, endodermal) -derived tissue) (multipotency) constituting a living body (other than placenta), and embryonic stem cells (ES cells) are included in the induced pluripotent stem cell. "induced pluripotent stem cells" are obtained from fertilized eggs, cloned embryos, regenerative stem cells, and stem cells in tissues. Cells having an artificial differentiation multipotency (also referred to as artificial pluripotent stem cells) similar to the differentiation multipotency of embryonic stem cells after the introduction of several genes into somatic cells are also included in pluripotent stem cells. Induced pluripotent stem cells can be prepared by methods known per se.
In the present invention, wnt agonists include, but are not limited to, wnt family, R-spondin mimetic, norrin, GSK-inhibitor, RNF43 inhibitor or ZNRF3 inhibitor.
In some embodiments, WNT agonists may include secreted glycoproteins (Wnt family) including, but not limited to, wnt-l/Int-1, wnt-2/Irp (InM-related protein), wnt-2b/13, wnt-3/Int-4, wnt-3a (R & D system), wnt-4, wnt-5a, wnt-5b, wnt-6 (Kirikoshi H et al, 2001Biochem Biophys Res Com 283 798-805), wnt-7a (R & D system), wnt-7b, wnt-8a/8D, wnt-8b, wnt-9a/14, wnt-9b/14b/15, wnt-10a, wnt-10b/12, wnM l, and Wnt-16.
In some embodiments, wnt agonists may include the R-spondin family of secreted proteins that are involved in the activation and modulation of the Wnt signaling pathway and consist of 4 members (R-spondin 1 (NU 206, nuvelo, san Carlos, CA), R-spondin2 ((R & D system), R-spondin3 and R-spondin-4) and Norrin (also known as Nome disease protein or NDP) (R & D system), which are secreted regulatory proteins that function the same as Wnt proteins in that they bind to the frizzled-4 receptor with high affinity and induce activation of the Wnt signaling pathway (Kestutis Planutis et al, (2007) BMC Cell Biol 8 12).
In some embodiments, the one or more Wnt agonists used in the invention may be R-spondin mimetics, e.g., agonists of Lgr5, such as anti-Lgr 5 antibodies. Small molecule agonists of the Wnt signaling pathway, which are aminopyrimidine derivatives, have been recently identified and are also explicitly listed as Wnt agonists (Lm et al (2005) AngewChem Int Ed Engl 44,1987-90).
In some embodiments, the Wnt agonist is an inhibitor of RNF43 or ZNRF 3. The inventors have found that RNF43 and ZNRF3 are present in the cell membrane and down regulate the level of Wnt receptor complex in the membrane, possibly through ubiquitination of frizzled proteins. Thus, the inventors hypothesize that inhibition of RNF43 or ZNRF3 with antagonistic antibodies, RNAi or small molecule inhibitors would indirectly stimulate the Wnt pathway. RNF43 and ZNRF3 have catalytic loop domains (with ubiquitination activity) that can be used as targets in small molecule inhibitor design. Various anti-RNF 43 antibodies and various anti-ZNRF 3 antibodies are commercially available. In some embodiments, such antibodies are suitable Wnt agonists in the context herein.
In some embodiments, the Wnt agonist may be a GSK-inhibitor. Known GSK-inhibitors include small interfering RNAs (siRNA), lithium (Sigma), and FRAT-family members and FRAT-derived peptides that inhibit GSK-3 interactions with axins. In the present invention, the Wnt agonist is a GSK-3 inhibitor, and the GSK-3 inhibitor includes but is not limited to a GSK-3 alpha inhibitor or a GSK-3 beta inhibitor. Examples of GSK-3β inhibitors include, but are not limited to CHIR99021, TD114-2, BIO (6-bromoindirubin-30-acetoxime), kenpaullone, TWS119, CBM1078, SB216763, 3F8 (tocis), AR-a014418, FRATide, indirubin-3' -oxime or L803. In specific embodiments of the invention, CHIR99021 is added to the medium until the final concentration is 50nM to 100 μm, e.g., 100nM to 50 μm, 1 μm to 30 μm, 1 μm to 15 μm, 5 μm, or 15 μm. Preferably, the concentration of CHIR99021 is 12 μm.
In the present invention, examples of the TGF- β superfamily include, but are not limited to, TGF- β proteins (including TGF- β3), bone Morphogenic Proteins (BMPs) (including BMP2, BMP4, BMP6, or BMP 7), growth Differentiation Factors (GDF), glial-derived neurotrophic factors (GDNF), activin, lefty, mulllerian inhibitory substances (Mu lllerian Inhibiting Substance, MIS), inhibin, or Nodal. In a specific embodiment of the invention, the TGF- β superfamily is BMP4. The final concentration of BMP4 is 1-100ng/mL, e.g., 1-80ng/mL, 1-60ng/mL, 1-40ng/mL, 10-40ng/mL, 20-40ng/mL; further, the final concentration of BMP4 was 30ng/mL.
In the present invention, the term "culture medium" is well-known in the art and generally refers to any substance or formulation used to culture living cells. The term "medium" as used in reference to cell culture includes components of the surrounding environment of the cell. The medium may be solid, liquid, gas or a mixture of phases and materials. The medium includes liquid growth medium and liquid medium that does not sustain cell growth. The medium also includes gel-like media such as agar, agarose, gelatin, and collagen matrices. Exemplary gaseous media include a gas phase to which cells grown on a petri dish or other solid or semi-solid support are exposed. The term "medium" also refers to a material intended for cell culture, even though the material has not been in contact with cells. In other words, the nutrient-rich liquid to be used for the culture is the medium. The term "basal medium" refers to a medium that promotes the growth of many types of microorganisms that do not require any special nutritional supplements. Most basal media generally comprise four basic chemical groups: amino acids, carbohydrates, inorganic salts and vitamins. Basal media are generally used as the basis for more complex media to which supplements such as serum or serum substitutes, buffers, growth-promoting factors, antibiotics, etc. are added. Examples of basal media include, but are not limited to, one or more of Eagle Basal Medium (BME), minimal Essential Medium (MEM), duibecco's Modified Eagle Medium (DMEM), medium 199, nutrient mixtures HamsF10 (F10) and HamsF12 (F12), mcCoy's 5A, duIbecco ' sMEM/F-12 (DMEM/F12), RPMI 1640, iscove's Modified Duibecco's Medium (IMDM), L-15 medium, neurobasal. In a specific embodiment of the invention, the basal medium is DMEM/F12 medium and neurobasal medium.
In the present invention, the serum replacement in the medium has a meaning well known to those skilled in the art, and refers to a composition or formulation used as a serum replacement in the course of culturing pluripotent stem cells while maintaining an undifferentiated state. That is, the serum replacement is capable of supporting the growth of embryonic stem cells or undifferentiated pluripotent stem cells without the need for serum supplementation. In certain exemplary embodiments, the serum replacement comprises: one or more amino acids, one or more vitamins, one or more trace metal elements. In some cases, the serum replacement may further comprise one or more components selected from the group consisting of: albumin, reduced glutathione, transferrin, insulin, and the like. Non-limiting examples of serum substitutes include, but are not limited to, knockOutTM SR (abbreviated as KOSR), KOSR CTS, N2 additive, CTS N2 additive, B27 additive, physiologix TM XF SR、StemSure TM SerumSubstitute Supplement、Knockout TM One or more of the SRs. In a specific embodiment of the invention, the serum replacement is a B27 additionAdditives and CTS N2 additives.
In the present invention, glutamine or a substitute thereof in a medium includes, but is not limited to: glutamine, L-alanyl-L-glutamine, L-glycyl-L-glutamine, N-acetyl-L-glutamine, hyCyte TM GluMax、glutaGRO TM Or a combination thereof. In a specific embodiment of the invention, the glutamine or a substitute thereof is glutamine.
In the present invention, antibiotics in the medium include, but are not limited to, one or more of Bacitracin (Bacitracin), neomycin (Neomycin), erythromycin (Erythromycin), chloramphenicol (chlormphenicol), penicillin-streptomycin, gentamicin, vancomycin. Additional antibiotic substances for use in the present invention will be apparent to those of ordinary skill in the art.
In the present invention, examples of Vascular Endothelial Growth Factor (VEGF) in the medium include, but are not limited to, one or more of VEGF-A, VEGF-B, VEGF-C, VEGF-D, PGF; preferably, the VEGF is VEGF-A. The concentration of VEGF-A may be, for example, 1-500ng/mL,1-400ng/mL,1-300ng/mL,1-200ng/mL. In Sub>A specific embodiment of the invention, the concentration of VEGF-A is 100ng/mL.
In the present invention, examples of Fibroblast Growth Factor (FGF) in the medium include, but are not limited to, one or more of FGF-1, FGF-2 (bFGF), FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23. In a specific embodiment of the invention, FGF is FGF-2. The concentration of FGF-2 may be, for example, 1-500ng/mL,1-400ng/mL,1-300ng/mL,1-200ng/mL. In a specific embodiment of the invention, the concentration of FGF is 100ng/mL.
In the present invention, cAMP activators in the medium may include one or more of forskolin, IBMX, rolipram, 8BrcAMP, prostaglandin E2 (PGE 2), NKH 477, dibutyl-cAMP (DBcAMP), sp-8-Br-cAMPs. The concentration of a cAMP activator inhibitor such as forskolin may be, for example, 0.1. Mu.M to 100. Mu.M, for example, 1. Mu.M to 50. Mu.M, for example, 5. Mu.M to 20. Mu.M. In a specific embodiment of the invention, the concentration of forskolin is 2 μm.
In the present invention, the term "extracellular matrix (ECM)" is secreted by connective tissue cells and comprises a variety of polysaccharides, water, elastin, and glycoproteins, including Collagen (Collagen), fibronectin, entactin, and laminin. Different types of ECM are known, which include different compositions, such as containing different types of glycoproteins or different combinations of glycoproteins. Examples of cells producing extracellular matrix are chondrocytes mainly producing collagen and proteoglycans, fibroblasts mainly producing type IV collagen, laminin, procollagen and fibronectin, and colon myofibroblasts mainly producing collagen (I, III and V), chondroitin sulfate proteoglycans, hyaluronic acid, fibronectin and myoglycoprotein C. The polysaccharides, elastin, glycoproteins, collagen, fibronectin, entactin and laminin contained in ECM are various polysaccharides, elastin, glycoproteins, collagen, fibronectin, entactin and laminin contained in ECM known in the art. For example, collagen may be Collagen-I, collagen-II, collagen-III, collagen-IV, collagen-V, collagen-VI or Collagen-VII, which are well known in the art to be incorporated into native ECMs.
ECMs suitable for use herein are available from commercial sources. Examples of commercially available extracellular matrices include extracellular matrix proteins (Invitrogen, R&D systems) and matrigel (Matrixgel TM BD Biosciences), and the like. In particular embodiments of the invention, the extracellular matrix includes collagen and Matrigel; further, the Collagen is Collagen-I.
In the present invention, the term "serum-free medium" or "SFM medium" is a medium that is serum-free (e.g., fetal Bovine Serum (FBS), calf serum, horse serum, goat serum, human serum, etc.) and is generally indicated by the letter SFM. Exemplary but non-limiting serum-free media familiar to those skilled in the art include HuMEC basal serum-free media, KNOKOKOUTTM CTSTM exotic ESC/iPSC media, STEMPROTM-34SFM media, STEMPROTM NSC media, ESSENTIALTM-8 media, media 254, media 106, media 131, media 154, media 171, media 200, media 231, heptoZYME-SFM, human endothelial-SFM, FREESTYLETM 293 expression media, media 154CF/PRF, media 154C, media 154CF, media 106, media 200PRF, media 131, essentialTM-6 media, STEMPROTM-34 media astrocyte medium, AIM medium CTSTM, AMINOMAXTM C-100 basal medium, AMINOMAXTM-II complete medium, CD FORTICHOTM medium, CDCHO AGT medium, CHO-S-SFM medium, FREESTYLETM CHO expression medium, CD OPTICHOTM medium, CD CHO medium, CDDG44 medium, SF-900TM medium, EXPI293TM expression medium, LHC basal medium, LHC-8 medium, 293SFM medium, CD 293 medium, AEM growth medium, per. Cell medium, AIM medium, culture medium, keratinocyte-SFM medium, LHC-8 medium, LHC-9 medium, and any derivatives or modifications thereof.
In the present invention, the term "treatment" refers to (1) preventing the appearance of symptoms or disease in a subject who is susceptible to or has not yet displayed a condition; (2) inhibiting the disease or preventing its progression or recurrence; or (3) ameliorating or causing regression of the disease or condition. As understood in the art, "treatment" is a method for achieving a beneficial or desired result, including clinical results. For the purposes of this technology, a beneficial or desired result can include, but is not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of a disorder (including a disease), stabilized (i.e., not worsening) state of a disorder (including a disease), delay or slowing of a disorder (including a disease), progression, amelioration or palliation of the disorder (including a disease), state, and remission (whether partial or total), whether detectable or not.
The invention will now be described in further detail with reference to the drawings and examples. The following examples are only illustrative of the present invention and are not intended to limit the scope of the invention. Simple modifications of the invention in accordance with the essence of the invention are all within the scope of the invention as claimed.
EXAMPLE 1 construction of Induced Pluripotent Stem Cells (iPSC) from patients with smog disease
1. Experimental method
Skin tissue from patients with RNF213 mutations were selected, approximately 4mm x 4mm, isolated and cultured as dermal fibroblasts (MEFs), and reprogrammed to ipscs using sendai virus reprogramming kit. Cells were plated onto MEFs for co-culture following Sendai virus infection. After infection, typical human embryonic stem cell-like clones are picked, mechanically separated and gently blown off into small cell clusters, passaged onto new feeder cells, mechanically passaged for more than two generations, and then continuously passaged by collagenase, the cell clones are kept in an undifferentiated state and are typical in morphology, and the construction of iPSC is completed. Expression of stem cell pluripotency markers (nuclear transcription factor OCT4, NANOG) was detected by immunofluorescent staining.
2. Experimental results
The results of the iPSC construction experiments are shown in fig. 1 and demonstrate successful reprogramming of skin tissue from patients with RNF213 mutant smoke to iPSC.
The immunofluorescence detection experiment results are shown in fig. 2, and the results show that the iPS cell line positively expresses nuclear transcription factors OCT4 and NANOG, which indicate that the skin tissues of patients carrying RNF213 mutant smog are successfully reprogrammed to iPSC.
Example 2 cultivation of vascular organoids Using smog-infected patient-derived iPSCs
1. Experimental method
Stage 1: induction of differentiation of iPSC into mesoderm (Day 0-3)
Differentiation can be started when the confluence of the iPSC reaches 40-70%. Starting on Day0 (Day 0), WNT signaling was activated by addition of CHIR99021 and incubated with BMP4 for 3 days. The culture medium was mixed DMEM/F12 medium, neurobasal medium, B27 additive, N2 additive, glutamine, β -mercaptoethanol (1:100), penicillin-streptomycin, 12 μm CHIR99021 and 30ng/mL BMP-4, and the aggregates were transferred to low adhesion plate cultured cells, induced to differentiate into mesoderm.
Stage 2: induction of vascular network structure (Day 3-10)
The mesoderm obtained in stage 1 was switched to vascular induction medium containing VEGF-A for 2 days (Day 3-4). The culture medium was Sub>A mixed DMEM/F12 medium, sub>A neurobasal medium, sub>A B27 supplement, an N2 supplement, glutamine, betSub>A-mercaptoethanol (1:100), penicillin-streptomycin, 100ng/mL VEGF-A, and 2. Mu.M forskolin (forskolin).
Day5 (Day 5), cell aggregates were embedded in a 3D collagen I-Matrigel matrix in 12-well plates, as follows: 2.0mg/mL type I Collagen solution (Collagen I) was prepared, and 0.1N NaOH, 10 XDMEM, HEPES, 7.5% sodium bicarbonate, glutamine (Glutamax) and Ham's F-12 were mixed, and the pH of the Collagen I solution was measured rapidly with a pH indicator strip and found to be 7.4. Mixing the Collagen I-Matrigel according to the ratio of 4:1, and planting the aggregates in the Collagen I-Matrigel matrix to ensure that the aggregates are uniformly distributed; the gel was allowed to set by incubation at 37℃for 2h. The medium was human endothelial SFM medium, 15% FBS, 100ng/mL VEGF-A and 100ng/mL FGF-2, and vascular differentiation and sprouting were induced.
Stage 3: formation of vascular organoids
The whole matrigel was free from the bottom of the well using the rounded end of sterile forceps. The gel was transferred to the lid of a 10cm dish under aseptic conditions using a sterile laboratory spoon. Two sterile 30 gauge needles were used to sever the single vascular network and minimize the amount of excess matrix around the organoids. Single organoids were transferred to 6-well low-attachment plates, and organoids were cultured by adding human endothelial SFM medium, 15% FBS, 100ng/mL VEGF-A, and 100ng/mL FGF-2.
Immunofluorescence techniques detect the expression of cell-specific markers (endothelial cell CD31 markers, smooth muscle cell markers).
2. Experimental results
The experimental results are shown in fig. 3, and the results show that the vascular organoid model is successfully constructed.
Example 3 blood vessel organoid function verification experiment
1. Experimental method
The vascular organoids cultured in example 2 were verified to be smoke disease organoids using single cell sequencing experiments and flow cytometry experiments, as follows:
single cell sequencing method: 40-50 organoids were collected from each group, washed with DPBS and minced with a scalpel. Organoids were transferred to DPBS solutions containing neutral protease enzyme and collagenase. Incubate at 37℃for 20 to 30 minutes. And centrifuged at 300g for 5 minutes at 4 ℃. The cell pellet was resuspended in HBSS, filtered through a cell filter, and centrifuged again at 300g for 5 minutes at 4 ℃ and resuspended in 2% FBS, the cells counted and diluted to the appropriate concentration of 10,000 cells for 10 x single cell sequencing.
The flow experimental method comprises the following steps: the organoid was digested with Ackutase cell dissociation solution to form a single cell suspension. Approximately 1X 10≡6 single cells per group were incubated with Alexa 488-labeled CD31 antibody (1:1000 dilution, BD) for 30 min. The results were analyzed using FlowJo software.
2. Experimental results
The experimental results are shown in fig. 4 and 5, and the results show that the cell annotation is carried out by single cell sequencing, the proportion of smooth muscle in the smoke disease group is higher than that of the healthy control group, and the results are verified by flow analysis to be consistent with the increase of smooth muscle which is the pathological feature of the smoke disease, and the disease phenotype is simulated.
The above description of the embodiments is only for the understanding of the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that several improvements and modifications can be made to the present invention without departing from the principle of the invention, and these improvements and modifications will fall within the scope of the claims of the invention.
Claims (10)
1. A method for constructing a smog vessel organoid model, which is characterized by comprising the following steps:
(1) Inducing differentiation of ipscs derived from smog patients into mesoderm;
(2) Inducing mesoderm described in step (1) to produce a vascular network structure;
(3) The vascular network structure described in the culturing step (2) is formed into a vascular organoid model.
2. The construction method according to claim 1, wherein the specific steps of step (1) include: inducing differentiation of the ipscs using a medium containing WNT agonist and TGF- β superfamily to obtain mesoderms;
preferably, the WNT agonist comprises one or more of the WNT family, the R-spondin family, norrin, GSK-inhibitor, RNF43 inhibitor or ZNRF3 inhibitor;
preferably, the GSK-inhibitor comprises a GSK-3 inhibitor;
preferably, the GSK-3 inhibitor comprises a GSK-3 a inhibitor or a GSK-3 β inhibitor;
preferably, the GSK-3 ss inhibitor comprises CHIR99021, TD114-2, BIO, kenpaullone, TWS119, CBM1078, SB216763, TOCRIS, AR-A014418, FRATide, indirubin-3' -oxide or L803;
preferably, the GSK-3β inhibitor is CHIR99021;
preferably, the concentration of CHIR99021 is 12 μm;
preferably, the TGF- β superfamily comprises TGF- β proteins, BMP, GDF, GDNF, activin, lefty, mulllerian inhibitor, inhibin, or Nodal;
preferably, the BMP comprises BMP2, BMP4, BMP6, or BMP7;
preferably, the BMP is BMP4;
preferably, the concentration of BMP4 is 30ng/mL;
preferably, the medium containing WNT agonist and TGF- β superfamily further comprises basal medium, serum replacement, glutamine or its replacement, sulfhydryl reducing agent, antibiotic;
preferably, the specific step of the step (2) includes:
(a) Inducing differentiation of the mesoderm to obtain vascular cells;
(b) Embedding the vascular cells in the step (a) in an extracellular matrix for incubation, and inducing differentiation and sprouting of the vascular cells by using a culture medium containing VEGF and FGF after incubation to obtain a vascular network structure;
preferably, the mesoderm is induced to differentiate using a medium containing VEGF and cAMP agonists;
preferably, the VEGF comprises one or more of VEGF-A, VEGF-B, VEGF-C, VEGF-D, PGF;
preferably, the VEGF is VEGF-A;
preferably, the concentration of VEGF-A is 100ng/mL;
preferably, the cAMP agonist comprises one or more of forskolin, IBMX, rolipram, 8BrcAMP, PGE2, NKH 477, DBcAMP, sp-8-Br-cAMPs;
preferably, the cAMP agonist is forskolin;
preferably, the concentration of forskolin is 2 μm;
preferably, the FGF comprises one or more of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23;
preferably, the FGF is FGF-2;
preferably, the FGF-2 is provided at a concentration of 100ng/mL;
preferably, the extracellular matrix comprises one or more of collagen, matrigel, gelatin, laminin, fibronectin, hyaluronic acid, and chitosan;
preferably, the extracellular matrix is collagen and Matrigel;
preferably, the Collagen comprises Collagen-I, collagen-II, collagen-III, collagen-IV, collagen-V, collagen-VI or Collagen-VII;
preferably, the Collagen is Collagen-I;
preferably, the concentration of the Collagen-I is 2.0mg/mL;
preferably, the pH of the Collagen-I is 7.4;
preferably, the mixing ratio of the collagen to Matrigel is 4:1;
preferably, the incubation conditions are 37 ℃ for 2 hours;
preferably, the extracellular matrix is further mixed with NaOH, DMEM, HEPES, sodium bicarbonate, glutamine, ham's F-12;
preferably, the concentration of sodium bicarbonate is 7.5%; preferably, the culture medium containing VEGF and cAMP agonists further comprises basal medium, serum replacement, glutamine or its replacement, sulfhydryl reducing agent, antibiotics;
preferably, the culture medium containing VEGF and FGF also comprises SFM culture medium and serum;
preferably, the serum comprises FBS, calf serum, horse serum, goat serum or human serum;
preferably, the serum is FBS;
preferably, the specific step of the step (3) includes: the vascular network structure described in step (2) was cultured with a medium containing VEGF and FGF to form a vascular organoid model.
3. The method of claim 2, wherein the basal medium comprises one or more of DMEM, IMDM, DMEM/F12, F10, BME, MEM, neurobasal;
preferably, the basal medium is DMEM/F12 medium and neurobasal medium.
4. The construction method according to claim 2, wherein the serum replacement comprises KOSR, B27 additive, N2 additive, physiologix TM XF SR、StemSure TM SerumSubstitute Supplement、Knockout TM One or more of the SRs;
preferably, the serum replacement is a B27 additive and an N2 additive;
preferably, the glutamine or a substitute thereof comprises glutamine, L-alanyl-L-glutamine, hyCyte TM GluMax、glutaGRO TM One or more of the following;
preferably, the glutamine or a substitute thereof is glutamine;
preferably, the sulfhydryl reducing agent comprises one or more of beta-mercaptoethanol and dithiothreitol;
preferably, the sulfhydryl reducing agent is beta-mercaptoethanol;
preferably, the antibiotics comprise one or more of penicillin-streptomycin, gentamicin and vancomycin;
preferably, the antibiotic is penicillin-streptomycin.
5. The method of claim 1, wherein the pathway for obtaining ipscs of smoky patient origin comprises commercial purchase or self-construction;
preferably, the smoke patient is a smoke patient carrying a mutation in RNF 213.
6. A smog disease vascular organoid model, characterized in that it is obtained by a construction method according to any one of claims 1-5.
7. Use of the organoid model of claim 6 for screening for a medicament for the prevention and/or treatment of smog disorders.
8. Use of a smog disease vascular organoid model of claim 6 in the manufacture of a product for evaluating the efficacy of a smog disease treatment drug.
9. Use of a smoky vascular organoid model according to claim 6 for evaluating a smoky detection product or method of non-diagnostic interest.
10. Use of the smoke disease organoid model of claim 6 for constructing a smoke disease animal model.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310888004.7A CN116875535B (en) | 2023-07-19 | 2023-07-19 | Smog disease vascular organoid model and construction method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310888004.7A CN116875535B (en) | 2023-07-19 | 2023-07-19 | Smog disease vascular organoid model and construction method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116875535A true CN116875535A (en) | 2023-10-13 |
CN116875535B CN116875535B (en) | 2024-07-12 |
Family
ID=88267832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310888004.7A Active CN116875535B (en) | 2023-07-19 | 2023-07-19 | Smog disease vascular organoid model and construction method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116875535B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117143807A (en) * | 2023-10-30 | 2023-12-01 | 北京大学 | Vascular organoid, preparation method thereof, cell treatment composition and application thereof in ischemic diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109576155A (en) * | 2018-12-18 | 2019-04-05 | 大连理工大学 | General nervous system chip |
CN111065731A (en) * | 2017-06-16 | 2020-04-24 | Imba-莫利库尔生物技术研究所 | Vascular organoids, methods of making and using the same |
US20200172879A1 (en) * | 2017-03-03 | 2020-06-04 | Obsidian Therapeutics, Inc. | Dhfr tunable protein regulation |
CN111417716A (en) * | 2017-11-30 | 2020-07-14 | 公立大学法人横滨市立大学 | Construction of three-dimensional organs from pluripotent stem cells |
WO2021076617A1 (en) * | 2019-10-14 | 2021-04-22 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
CN115851578A (en) * | 2022-12-23 | 2023-03-28 | 华南理工大学 | Kit for continuously amplifying hepatic progenitor cell organoid and/or hepatic cell organoid by 3D suspension induction and application thereof |
-
2023
- 2023-07-19 CN CN202310888004.7A patent/CN116875535B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200172879A1 (en) * | 2017-03-03 | 2020-06-04 | Obsidian Therapeutics, Inc. | Dhfr tunable protein regulation |
CN111065731A (en) * | 2017-06-16 | 2020-04-24 | Imba-莫利库尔生物技术研究所 | Vascular organoids, methods of making and using the same |
CN111417716A (en) * | 2017-11-30 | 2020-07-14 | 公立大学法人横滨市立大学 | Construction of three-dimensional organs from pluripotent stem cells |
CN109576155A (en) * | 2018-12-18 | 2019-04-05 | 大连理工大学 | General nervous system chip |
WO2021076617A1 (en) * | 2019-10-14 | 2021-04-22 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
CN115851578A (en) * | 2022-12-23 | 2023-03-28 | 华南理工大学 | Kit for continuously amplifying hepatic progenitor cell organoid and/or hepatic cell organoid by 3D suspension induction and application thereof |
Non-Patent Citations (3)
Title |
---|
ISABELLA CANAVERO 等: "Clinical Management of Moyamoya patients", 《JOURNAL OF CLINICAL MEDICINE》, vol. 10, no. 16 * |
KIRILL SALEWSKIJ 等: "Blood Vessel Organoids for Development and Disease", 《CIRCULATION RESEARCH》, vol. 132, no. 4 * |
YIMENG XUE 等: "Association of RNF213 Variants With Periventricular Anastomosis in Moyamoya Disease", 《STROKE》, vol. 53, no. 9 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117143807A (en) * | 2023-10-30 | 2023-12-01 | 北京大学 | Vascular organoid, preparation method thereof, cell treatment composition and application thereof in ischemic diseases |
Also Published As
Publication number | Publication date |
---|---|
CN116875535B (en) | 2024-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210102177A1 (en) | Derivation of human skin organoids from pluripotent stem cells | |
Montesano et al. | Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors | |
AU2009228756B2 (en) | Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations | |
CN109136185B (en) | Preparation method and application of brain-like organ device | |
JP2018531027A6 (en) | Induction of human skin organoids from pluripotent stem cells | |
WO2021254296A1 (en) | Bioactive substance composition, serum-free culture medium comprising the composition, and uses thereof | |
JP2011525370A (en) | Method for preparing human skin substitutes from human pluripotent stem cells | |
JP2011525370A5 (en) | ||
CA3140619C (en) | Improved retinal organoids and methods of making the same | |
CN116875535B (en) | Smog disease vascular organoid model and construction method thereof | |
TW201522638A (en) | Method for preparing pluripotent stem cells | |
CN109689858A (en) | Method for generating mesoderm and/or endothelium colony forming cell like cell with body vessel Forming ability | |
KR20230042365A (en) | Mass production of human pluripotent stem cell-derived cardiac stromal cells | |
TW202122573A (en) | Compositions and methods of treating vascular diseases | |
Chen et al. | Formation of keratocyte spheroids on chitosan-coated surface can maintain keratocyte phenotypes | |
Chang et al. | CD90+ cardiac fibroblasts reduce fibrosis of acute myocardial injury in rats | |
EP4289941A1 (en) | Method for reprogramming cell | |
WO2009080794A1 (en) | Method for preparing cell-specific extracellular matrices | |
Li | Culture methods for selective growth of normal rat and human Schwann cells | |
JP2005531298A (en) | Redifferentiated cells to repair cartilage defects | |
CN114317404A (en) | Culture medium formula suitable for in-vitro culture of hair follicle stem cells and culture method for in-vitro 3D hair follicle stem cells | |
CN115786245B (en) | Human bionic lung organoid construction method | |
WO2023157852A1 (en) | Method for inducing differentiation from pluripotent stem cell to epidermal keratinocyte | |
WO2012009538A2 (en) | Adipocyte-derived membrane extract with biological activity | |
CN117701492A (en) | Construction method and application of liver organ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |